View:
Download DOC
Download PDF
Download XLS
Lifevantage Corporation (Form: 8-K)  

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   October 29, 2008

Lifevantage Corporation
__________________________________________
(Exact name of registrant as specified in its charter)

     
Colorado 000-30489 90-0224471
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
11545 W. Bernardo Court, Suite 301, San Diego, California   92127
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   858-312-8000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 8.01 Other Events.

On October 29, 2008, Lifevantage Corporation (the "Company") announced that the Company is entering the network marketing industry via independent distributorships in a press release entitled, "LifeVantage Announces Launch of Protandim® Into Multi-Billion Dollar Network Marketing Sales Channel." The Company will continue to have a retail and direct to consumer presence in addition to the independent distributorships.

The press release is attached as Exhibit 99.1 hereto, which is furnished under Item 8.01 of this report and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, regardless of any general incorporation language in such filing.





Item 9.01 Financial Statements and Exhibits.

99.1 Press release, dated October 29, 2008, entitled, "LifeVantage Announces Launch of Protandim® Into Multi-Billion Dollar Network Marketing Sales Channel."





Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Lifevantage Corporation
          
October 31, 2008   By:   /s/ Bradford K. Amman
       
        Name: Bradford K. Amman
        Title: Chief Financial Officer

Top of the Form

Exhibit Index


     
Exhibit No.   Description
 
99.1
  Press release, dated October 29, 2008, entitled, “LifeVantage Announces Launch of Protandim® Into Multi-Billion Dollar Network Marketing Sales Channel.”
EX-99.1

FOR IMMEDIATE RELEASE NEWS

October 29, 2008 OTCBB: LFVN

Contact: Jan Strode (619) 890-4040

Jean Golden

(612) 385-2324

LifeVantage Announces Launch of Protandim® into Multi-Billion Dollar Network
Marketing Sales Channel.

SAN DIEGO, CA, October 29, 2008 – Protandim® (www.Protandim.com), the only product clinically proven to slow the progressive rate of aging, announced today that it is entering the multi-billion dollar network marketing industry via independent distributorships offered by the product’s maker, LifeVantage Corporation (OTCBB: LFVN). The company will continue to have a retail presence, in addition to the independent distributorships.

David Brown, LifeVantage President and CEO said, “Network marketing is by far the fastest growing sales channel for dietary supplements. We know that the Protandim® story is one that resonates with customers and makes them want to share the product’s tremendous benefits with others. In the past, we have had many requests for independent distributorship opportunities with the Company. Until now that option was not available.”

Brown continued, “This latest step in our commitment to introduce Protandimâ into multiple sales channels is marked by the success we have had in recruiting successful network marketing professionals and distributors who have previously been instrumental in the success of some of the largest network marketing companies in the industry.”

Tom Aarts, Managing Director of Nutrition Business Advisors, and Co-Founder of The Nutrition Business Journal endorses the Company’s decision to pursue the network marketing channel. “Over $100 billion dollars a year are spent fighting aging. In the U.S. alone, the network marketing industry accounts for $7.9 billion in sales. I believe Protandim will do exceptionally well with the network marketing business model, because this model allows the distributors the opportunity to fully explain the product’s benefits and uses, a key advantage of this distribution model,” he said.

In commenting further on the Company’s move, Brown added, “In addition to offering a product that is unparalleled in any sales channel, we have worked with InfoTrax Systems, a leading developer of commission tracking software, to develop a commission plan that we believe will be one of the best in the industry. We are combining the enthusiasm that our product inspires, with the opportunity to build a successful home-based business in the trillion dollar health care industry. With the benefits and science of Protandimâ, we have the opportunity to be the next great success story in an industry known for producing such fast-growing companies as Mona Vie, Xango and others.”

About Protandim®
Protandim® is a groundbreaking, clinically proven solution for healthy aging. This patented anti-oxidant therapy is 1000’s of times more powerful than red wine, oranges, blueberries, acai juice or other popular anti-oxidant supplements. Protandim works by increasing the body’s natural anti-oxidant protection at the cellular level, triggering cells to produce naturally occurring protective antioxidant enzymes such as super oxide dismutase (SOD), catalase, and glutathione.

A peer-reviewed scientific study shows that after 30 days of taking Protandim, free radicals decreased an average of 40 percent, slowing the progressive aging factors to the level of a 20 year old. Protandim is currently the subject of over 20 scientific studies at leading universities and research institutes. For more information, please visit the Protandim® product web site at www.Protandim.com or contact Jan Strode at (619) 890-4040.

About LifeVantage Corporation
LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science based, natural products company, dedicated to helping people reach their health and wellness goals through science-based solutions to oxidative stress. Founded in 2003 and based in San Diego, CA, LifeVantage develops nutraceutical products, including Protandim that leverage the company’s expertise and that are intended to deliver significant health benefits to consumers. For more information, visit www.LifeVantage.com or contact Jan Strode at (619) 890-4040.

This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company uses the words “anticipate,” “believe,” “could,” “should,” “estimate,” “expect,” “intend,” “may,” “predict,” “project,” “plan,” “target” and similar terms and phrases, including references to assumptions, to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the risk that government regulators and regulations could adversely affect our business; future laws or regulations may hinder or prohibit the production or sale of our existing product and any future products; unfavorable publicity could materially hurt our business; and the Company’s ability to protect our intellectual property rights and the value of our product. These and other risk factors are discussed in greater detail in the Company’s Annual Report on Form 10-KSB under the caption “Risk Factors”, and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

###